TABLE 54Maintenance transition matrix

MNT remissionMNT relapseMNT relapse 2TransitionalMNT surgeryMNT post-surgery remissionSC remissionSC relapseSC surgerySC post-surgical remission
MNT remission0.9837Rel 10.00690.0035
MNT relapseRESP#0.03480.0189
MNT relapse 2RESP#0.03480.0189
Transitional0.07130.87490.03480.0189
MNT surgery0.05210.01580.67090.2613
MNT post-surgery remission0.0054Rel 20.0026#
SC remissionSC transition matrix – Table 51
SC relapse
SC surgery
SC post-surgery remission

RESP represents either ACCENT_response (infliximab) or CHARM_response (adalimumab).

Rel 1 = 0.0059/(RESP/0.0713).

Rel 2 = 0.0011/(RESP/0.0713).

Shaded cells represent unused transitions.

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.